NasdaqGM:CRVSBiotechs
Corvus Trials Progress And Cash Raise Reframe Soquelitinib Risk Reward Profile
Corvus Pharmaceuticals has moved its lead candidate, soquelitinib, into late-stage Phase 3 and Phase 2 trials across several indications.
The company raised $189 million in a follow-on offering, which it says extends its cash runway into 2028.
Corvus Pharmaceuticals (NasdaqGM:CRVS) is drawing attention after pushing soquelitinib into more advanced clinical trials while securing fresh capital to support the work. The stock trades at $16.01, with very large 3-year and 1-year returns, and a...